The <i>FGFR3</i> Mutation is Related to Favorable pT1 Bladder CancerBas W.G. van Rhijn, Bharati Bapat, Theodorus van der Kwast et al.|The Journal of Urology|2011Cited by 102
Somatic mutations of KIT in familial testicular germ cell tumoursElizabeth Rapley, Michael R. Stratton, Radka Lohynská et al.|British Journal of Cancer|2004Cited by 96
FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†Bas W.G. van Rhijn, Tahlita C.M. Zuiverloon, Laura S. Mertens et al.|European Urology|2020Cited by 89
Prognostic value of molecular markers, sub‐stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancerBas W.G. van Rhijn, Alexandre R. Zlotta, Liyang Liu et al.|British Journal of Urology|2012Cited by 64
Molecular and clinical support for a four-tiered grading system for bladder cancer based on the WHO 1973 and 2004 classificationsBas W.G. van Rhijn, Theodorus van der Kwast, Mireía Musquera et al.|Modern Pathology|2014Cited by 47